Evidence map›Paper›PMID 27634430›Full record

ArticleClinical immunology (Orlando, Fla.)2016

Cross-reactive multifunctional CD4+ T cell responses against Salmonella enterica serovars Typhi, Paratyphi A and Paratyphi B in humans following immunization with live oral typhoid vaccine Ty21a.

Rezwanul Wahid, Stephanie Fresnay, Myron M Levine, Marcelo B Sztein

Abstract read
In one paragraph

Article in Clinical immunology (Orlando, Fla.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
6.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Antimicrobial resistance: new insights and therapeutic implications.Applied microbiology and biotechnology · 2022
    Review
  5. Article
  6. Article
  7. Review
  8. Evasion of MAIT cell recognition by the AfricanProceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  9. Microorganisms · 2020
    Review
  10. HumanClinical & translational immunology · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Association betweenHuman vaccines & immunotherapeutics · 2019
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Rezwanul WahidDepartment of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA.
Stephanie FresnayDepartment of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA.
Myron M LevineDepartment of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Medicine, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA.
Marcelo B SzteinDepartment of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Medicine, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: msztein@medicine.umaryland.edu.
University of Maryland, Baltimore · US

Funding

Vaccine strategy for broad spectrum protection agains non-typhoidal salmonellU54AI057168 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI GEDDES, CHRISTOPHER DARREN · 2003 to 2013
$91.5M
Wild-type S. typhi Infection in Humans: Integrated Immunoprotective MechanismsU19AI082655 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SZTEIN, MARCELO B. · 2009 to 2018
$27.8M
Shigella Live Vector-Based Multivalent VaccineU19AI109776 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LEVINE, MYRON MAX · 2014 to 2018
$25.4M
IMMUNE MECHANISMS OF PROTECTION IN S TYPHI VACCINESR01AI036525 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Marcelo B. Sztein · 1994 to 2026
$12.2M
NIAID NIH HHS R01 AI036525NIAID NIH HHS U19 AI082655NIAID NIH HHS U19 AI109776NIAID NIH HHS U54 AI057168
6 · The paper itself

Abstract

The live oral typhoid vaccine Ty21a elicits predominantly CD8+, as well as CD4+ T cells mediated immune responses. Clinical field studies showed that Ty21a is moderately effective against S. Typhi and S. Paratyphi B, but not S. Paratyphi A infections. In this study we describe the in depth characterization of S. Typhi, S. Paratyphi A and S. Paratyphi B cross-reactive CD4+ T cell responses elicited following immunization with Ty21a. PBMC samples were collected from 16 healthy volunteers before and 42/84days after Ty21a immunization and stimulated ex-vivo with Salmonella-infected targets. Multiparametric flow cytometry was used to detect the vaccine elicited Salmonella-specific responses in T effector/memory (T

Indexed as

Administration, OralAdultCD4-Positive T-LymphocytesCross ReactionsCytokinesHumansMiddle AgedPolysaccharides, BacterialSalmonella paratyphi ASalmonella paratyphi BSalmonella typhiTyphoid-Paratyphoid VaccinesVaccines, Live, UnattenuatedYoung AdultCytokinesPolysaccharides, BacterialTy21a typhoid vaccineTyphoid-Paratyphoid VaccinesVaccines, Live, UnattenuatedCD4 T cellsCross-reactiveHumanMultifunctionalSalmonellaTy21a

Identifiers

PMID27634430
PMCPMC5322816
OpenAlexW2521004414

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.